JGOG2033: Randomized phase III trial of whole pelvic radiotherapy vs cisplatin-based chemotherapy in patients with intermediate risk endometrial carcinoma

Sagae, S.; Udagawa, Yasuhiro; Susumu, Nobuyuki; Niwa, Kuniaki; Kudo, Ryuichi; Nozawa, Satoru

doi:10.1200/jco.2005.23.16_suppl.5002

Cited by 17 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results showed that both PFS and OS of postoperative chemotherapy were better than those of irradiation in the "high" intermediate risk (stage II and IIIa with positive cytology) group patients. 80 These studies suggest the possible advantage of postoperative chemotherapy to radiotherapy. Accordingly, more than 80% of patients of this category in Japan now undergo postoperative chemotherapy.…”

Section: Postoperative Therapymentioning

confidence: 96%

Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment

Shiozawa

Konishi

2006

Int J Clin Oncol

View full text Add to dashboard Cite

The number of patients with endometrial carcinoma is markedly increasing in Japan. Therefore, understanding of its biological characteristics and establishment of appropriate treatment are important. In this article, we first describe the clinicopathology of the two types of endometrial carcinoma with their hormonal background and genetic alterations, and then discuss the pathways of early endometrial carcinogenesis. In addition, we also review the diagnostic and therapeutic modalities for early endometrial carcinomas with current controversies, especially regarding postoperative treatment strategies.

show abstract

Section: Postoperative Therapymentioning

confidence: 96%

Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment

Shiozawa

Konishi

2006

Int J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Several clinicopathological parameters are currently used for the classification of risks for relapse and death, such as surgical stage, histological type, grade, depth of myometrial invasion, cervical stromal invasion, lymph node metastasis, lymph-vascular involvement, and peritoneal cytology (Morrow et al, 1991;Grigsby et al, 1992). For patients belonging to high or intermediate risk groups defined by these parameters, either postoperative adjuvant radiation therapy, or chemotherapy has been used (Creutzberg et al, 2000;Keys et al, 2004;Sagae et al, 2005). However, selecting the patients that will receive the adjuvant therapy, and its effectiveness, especially its impact on survival remain controversial (Cardenes and Randall, 2003).…”

mentioning

confidence: 99%

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer

et al. 2006

View full text Add to dashboard Cite

Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolising enzyme inducing immune tolerance. The present study aimed to investigate IDO expression and its prognostic significance in endometrial cancer. Indoleamine 2,3-dioxygenase expression in endometrial cancer tissues (n ¼ 80) was immunohistochemically scored as four groups (IDOÀ, 1 þ , 2 þ , and 3 þ ). The high IDO expression (IDO2 þ or 3 þ ) in tumour cells was found in 37 (46.3%) of the 80 cases, and was positively correlated with surgical stage, myometrial invasion, lymph-vascular space involvement, and lymph node metastasis, but not with the histological grade. Patients with high IDO expression had significantly impaired overall survival and progression-free survival (PFS) (P ¼ 0.002 and P ¼ 0.001, respectively) compared to patients with no or weak expression of IDO (IDOÀ or 1 þ ). The 5-year PFS for IDOÀ/1 þ , 2 þ , and 3 þ were 97.7, 72.9, and 36.4%, respectively. Even in patients with early-stage disease (International Federation of Gynecology and Obstetrics I/II, n ¼ 64), the PFS for IDO2 þ /3 þ was significantly poor (P ¼ 0.001) compared to that for IDOÀ/1 þ . On multivariate analysis, IDO expression was an independent prognostic factor for PFS (P ¼ 0.020). These results indicated that the high IDO expression was involved in the progression of endometrial cancer and correlated with the impaired clinical outcome, suggesting that IDO is a novel and reliable prognostic indicator for endometrial cancer.

show abstract

“…Similar rates of distant recurrence were seen in both groups. The results from this trial have not yet been published but have been presented at ASCO [64] and demonstrate no overall difference in either progression-free survival or overall survival.…”

Section: Adjuvant Chemotherapy In Endometrioid Diseasementioning

confidence: 83%

The modern management of endometrial cancer

Holland

Kitchener

2007

Oncol Rev

View full text Add to dashboard Cite

Endometrial cancer is a relatively common gynecological cancer which is increasing in incidence. Survival rates are generally good for those with early disease but a significant minority of women have high risk or advanced disease. Better treatments are required to improve outcomes for these women. There is increasing interest in the use of chemotherapy and improved understanding of the molecular biology of endometrial tumours may pave the way for the use of therapeutic biologic agents that target specific molecular pathways. Recent years have seen greater emphasis on an evidencebased approach to the management of women with endometrial cancer. Extended surgery and adjuvant therapy are now used selectively after individual risk assessment for each woman and there is increased interest in the use of chemotherapeutic agents in the adjuvant setting. This review addresses the modern management of endometrial cancer in the light of available evidence and highlights areas of controversy.

show abstract

JGOG2033: Randomized phase III trial of whole pelvic radiotherapy vs cisplatin-based chemotherapy in patients with intermediate risk endometrial carcinoma

Cited by 17 publications

References 0 publications

Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment

Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer

The modern management of endometrial cancer

Contact Info

Product

Resources

About